Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

Benralizumab, an anti–interleukin-5 receptor alpha monoclonal antibody, was significantly better than placebo at producing a histologic response of up to six eosinophils per high-power field ...

Benralizumab resulted in a 45-51% reduction in exacerbation rates compared to placebo (reduction from 3.0 to 0.73 per year for treatment every 4 weeks; ...

Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial, The Lancet Respiratory Medicine.

The antibody drug benralizumab is on the fast track to becoming the first new treatment for certain kinds of asthma and COPD flare-ups seen in 50 years, following promising clinical trial data.

Mepolizumab and benralizumab had similar safety profiles for patients with severe eosinophilic asthma despite their different mechanisms, according to a study published in The Journal of Allergy ...

The benralizumab group not only had fewer symptoms, but it also took longer for them to suffer an event so severe they had to either see a doctor or go to the hospital, researchers found.

Gastroenterology > General Gastroenterology Benralizumab Led to Histologic Responses in Eosinophilic Esophagitis — But there was no significant difference in symptom relief compared with placebo ...

Through this approval, Benralizumab is indicated as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).

Diagrammatic illustration of the mechanism of two monoclonal antibodies utilized for treating eosinophilic asthma, mepolizumab, and benralizumab. Mepolizumab specifically targets interleukin-5 (IL ...

Benralizumab is an anti-eosinophil monoclonal antibody that induces direct, rapid and near-complete depletion of eosinophils, with an onset of action within 24 hours as confirmed in early phase I ...

Find out how to take Benralizumab(drug) and its dose. Describes the best time to take the drug and precautions if any that should be followed.